Literature DB >> 29285614

The Effects of Quinine on Neurophysiological Properties of Dopaminergic Neurons.

Li Zou1, Yingchao Xue2, Michael Jones1, Thomas Heinbockel3, Mingyao Ying2, Xiping Zhan4.   

Abstract

Quinine is an antimalarial drug that is toxic to the auditory system by commonly inducing hearing loss and tinnitus, presumably due to its ototoxic effects on disruption of cochlear hair cells and blockade of ion channels of neurons in the auditory system. To a lesser extent, quinine also causes ataxia, tremor, and dystonic reactions. As dopaminergic neurons are implicated to play a role in all of these diseases, we tested the toxicity of quinine on induced dopaminergic (iDA) neurons derived from human pluripotent stem cells (iPSCs) and primary dopaminergic (DA) neurons of substantia nigra from mice brain slices. Patch clamp recordings and combined drug treatments were performed to examine key physiological properties of the DA neurons. We found that quinine (12.5-200 μM) depolarized the resting membrane potential and attenuated the amplitudes of rebound spikes induced by hyperpolarization. Action potentials were also broadened in spontaneously spiking neurons. In addition to quinine attenuating hyperpolarization-dependent conductance, the tail currents following withdrawal of hyperpolarizing currents were also attenuated. Taken together, we found that iPSC-derived DA neurons recapitulated all the tested physiological properties of human DA neurons, and quinine had distinct effects on the physiology of both iDA and primary DA neurons. This toxicity of quinine may be the underlying mechanism for the movement disorders of cinchonism or quinism and may play a role in tinnitus modulation.

Entities:  

Keywords:  Dopaminergic neuron; Hyperpolarization; Quinine; iPS cell

Mesh:

Substances:

Year:  2017        PMID: 29285614     DOI: 10.1007/s12640-017-9855-1

Source DB:  PubMed          Journal:  Neurotox Res        ISSN: 1029-8428            Impact factor:   3.911


  42 in total

1.  Structures of the Human HCN1 Hyperpolarization-Activated Channel.

Authors:  Chia-Hsueh Lee; Roderick MacKinnon
Journal:  Cell       Date:  2017-01-12       Impact factor: 41.582

2.  Treatment of depressed tinnitus patients with nortriptyline.

Authors:  M D Sullivan; R A Dobie; C S Sakai; W J Katon
Journal:  Ann Otol Rhinol Laryngol       Date:  1989-11       Impact factor: 1.547

Review 3.  Antidepressant therapy in tinnitus.

Authors:  Shannon K Robinson; Erik S Viirre; Murray B Stein
Journal:  Hear Res       Date:  2006-09-14       Impact factor: 3.208

4.  Quinine blockade of currents through Ca2+-activated K+ channels in bovine chromaffin cells.

Authors:  M I Glavinović; J M Trifaró
Journal:  J Physiol       Date:  1988-05       Impact factor: 5.182

5.  Carbamazepine reduces dopamine-mediated behavior in chronic neuroleptic-treated and untreated rats: implications for treatment of tardive dyskinesia and hyperdopaminergic states.

Authors:  Gerald J LaHoste; Tim Wigal; Bryan H King; Sabrina E B Schuck; Francis M Crinella; James M Swanson
Journal:  Exp Clin Psychopharmacol       Date:  2000-02       Impact factor: 3.157

6.  Dopamine prevents muscarinic-induced decrease of glutamate release in the auditory cortex.

Authors:  M Atzori; P O Kanold; J C Pineda; J Flores-Hernandez; R D Paz
Journal:  Neuroscience       Date:  2005       Impact factor: 3.590

Review 7.  Timing, space and ADHD: the dopamine theory revisited.

Authors:  F Levy; J M Swanson
Journal:  Aust N Z J Psychiatry       Date:  2001-08       Impact factor: 5.744

8.  Effects of quinine on neural activity in cat primary auditory cortex.

Authors:  K Ochi; J J Eggermont
Journal:  Hear Res       Date:  1997-03       Impact factor: 3.208

9.  Quinine potently blocks single K+ channels activated by dopamine D-2 receptors in rat corpus striatum neurons.

Authors:  J E Freedman; F F Weight
Journal:  Eur J Pharmacol       Date:  1989-05-19       Impact factor: 4.432

10.  Quinine-induced tinnitus in rats.

Authors:  P J Jastreboff; J F Brennan; C T Sasaki
Journal:  Arch Otolaryngol Head Neck Surg       Date:  1991-10
View more
  7 in total

1.  An in silico-in vitro pipeline for drug cardiotoxicity screening identifies ionic pro-arrhythmia mechanisms.

Authors:  Alexander P Clark; Siyu Wei; Darshan Kalola; Trine Krogh-Madsen; David J Christini
Journal:  Br J Pharmacol       Date:  2022-07-24       Impact factor: 9.473

2.  Role of Connexin 36 in Autoregulation of Oxytocin Neuronal Activity in Rat Supraoptic Nucleus.

Authors:  Ping Wang; Stephani C Wang; Dongyang Li; Tong Li; Hai-Peng Yang; Liwei Wang; Yu-Feng Wang; Vladimir Parpura
Journal:  ASN Neuro       Date:  2019 Jan-Dec       Impact factor: 4.146

Review 3.  Hydroxychloroquine and chloroquine: a potential and controversial treatment for COVID-19.

Authors:  Li Zou; Lijun Dai; Xingyu Zhang; Zhaohui Zhang; Zhentao Zhang
Journal:  Arch Pharm Res       Date:  2020-08-01       Impact factor: 6.010

4.  Synthetic mRNAs Drive Highly Efficient iPS Cell Differentiation to Dopaminergic Neurons.

Authors:  Yingchao Xue; Xiping Zhan; Shisheng Sun; Senthilkumar S Karuppagounder; Shuli Xia; Valina L Dawson; Ted M Dawson; John Laterra; Jianmin Zhang; Mingyao Ying
Journal:  Stem Cells Transl Med       Date:  2018-11-01       Impact factor: 6.940

Review 5.  Connexins-Based Hemichannels/Channels and Their Relationship with Inflammation, Seizures and Epilepsy.

Authors:  Laura Medina-Ceja; Juan C Salazar-Sánchez; Jorge Ortega-Ibarra; Alberto Morales-Villagrán
Journal:  Int J Mol Sci       Date:  2019-11-27       Impact factor: 5.923

Review 6.  Chloroquine to fight COVID-19: A consideration of mechanisms and adverse effects?

Authors:  Xiping Zhan; Sharon Dowell; Ying Shen; Dexter L Lee
Journal:  Heliyon       Date:  2020-09-09

Review 7.  Use of zebrafish larvae lateral line to study protection against cisplatin-induced ototoxicity: A scoping review.

Authors:  Ewa Domarecka; Magda Skarzynska; Agnieszka J Szczepek; Stavros Hatzopoulos
Journal:  Int J Immunopathol Pharmacol       Date:  2020 Jan-Dec       Impact factor: 3.219

  7 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.